甲基2-甲基-2-(苯氧基)丙酸酯 | 72278-52-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 甲基2-甲基-2-(苯氧基)丙酸酯
• 中文别名: 2-甲基[1,1'-联环己基]-2-基乙酸酯
• 英文名称: methyl 2-methyl-2-phenoxypropionate
• 英文别名: trimethylphenoxy acetic acid；Methyl 2-phenoxyisobutyrate；methyl 2-methyl-2-phenoxypropanoate
• CAS: 72278-52-5
• 化学式: C₁₁H₁₄O₃
• mdl: MFCD19348419
• 分子量: 194.23
• InChiKey: UAQIYYDCUSJYRL-UHFFFAOYSA-N

物化性质

• 密度：
  1.061[at 20℃]
• LogP：
  2.110 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  2-苯氧基丙酸甲酯	methyl 2-phenoxypropanoate	2065-24-9	C10H12O3	180.203
  2-苯氧基丙酸	2-phenoxypropionic acid	940-31-8	C9H10O3	166.177

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	2-(4-hydroxyphenoxy)-2-methylpropionic acid methyl ester	81466-36-6	C11H14O4	210.23
  2-甲基-2-苯氧基丙酸	2-methyl-2-phenoxypropionic acid	943-45-3	C10H12O3	180.203
  ——	methyl 2-(p-acetylphenoxy)-2-methylpropionate	42019-06-7	C13H16O4	236.268

反应信息

• 作为反应物：
  描述：

  甲基2-甲基-2-(苯氧基)丙酸酯 在 aluminum (III) chloride 、 水 、 sodium methylate 、 对甲苯磺酸 、 间氯过氧苯甲酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 2-(4-hydroxyphenoxy)-2-methylpropionic acid methyl ester
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016
• 作为产物：
  描述：

  2-氯-2-甲基丙酸甲酯 、 苯酚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 甲基2-甲基-2-(苯氧基)丙酸酯
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016

文献信息

• 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI.sub.2 derivatives
  申请人：Toray Industries, Inc.

  公开号：US04775692A1

  公开（公告）日：1988-10-04

  Disclosed herein are novel prostaglandin I.sub.2 (PGI.sub.2) derivatives exhibiting excellent in vivo duration and activities, said derivatives being represented by the general formula: ##STR1## wherein R.sub.1, X, R.sub.2 and R.sub.3 are as defined herein.

  本文披露了一种展现出优异体内持续时间和活性的新型前列腺素I.sub.2（PGI.sub.2）衍生物，所述衍生物由以下一般式表示：##STR1##其中R.sub.1、X、R.sub.2和R.sub.3如本文所定义。
• GHRH analogs
  申请人：The Administrators of The Tulane Educational Fund

  公开号：EP0413839A1

  公开（公告）日：1991-02-27

  There is provided a novel series of synthetic GHRH analog peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans, which are resistant to enzymatic degradation in the body in view of the provision of the omega-guanidino lower alkyl group at the terminal 28-position of the peptide.

  提供了一系列新型合成GHRH类似肽，这些肽在动物体内，包括人体内，极具激发垂体生长激素释放的强效能力，这是因为在肽的末端28位置提供了omega-胍基较低烷基基团，使其具有抗酶降解的特性。
• DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS
  申请人：Novira Therapeutics, Inc.

  公开号：US20160185779A1

  公开（公告）日：2016-06-30

  Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

  本文提供了用于治疗需要治疗HBV感染患者的化合物，其制药组合物，以及抑制、抑制或预防该患者HBV感染的方法。
• 1,3-Dioxane ethers
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0201351A2

  公开（公告）日：1986-11-12

  The invention concerns novel 1,3-dioxane ethers of the formula I, wherein R1 includes alkyl, cycloalkyl, phenyl and phenylalkyl, R2 and R3 include hydrogen and alkyl, n is 1 or 2, m is 2, 3 or 4, p is zero, 1 or 2, and Z is carboxy or 1 (H)-tetrazol-5-yl, and pharmaceutically acceptable salts thereof, for use in conjunction with their pharmaceutical compositions in the treatment of certain pulmonary and/or vascular disorders. The invention also describes various processes and intermediates for the manufacture of the novel compounds.

  本发明涉及式 I 的新型 1,3-二氧六环醚，其中 R1 包括烷基、环烷基、苯基和苯基烷基，R2 和 R3 包括氢和烷基，n 为 1 或 2，m 为 2、3 或 4，p 为 0、1 或 2，Z 为羧基或 1 (H)-tetrazol-5-yl 及其药学上可接受的盐类，可与它们的药物组合物一起用于治疗某些肺部和/或血管疾病。 本发明还描述了制造这些新型化合物的各种工艺和中间体。
• Therapeutic agents
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0266979A2

  公开（公告）日：1988-05-11

  The invention concerns novel therapeutic agents containing a (Z)-(2-alkoxyalkyl- or 2-aryloxyalkyl-4-phenyl-1,3-­dioxan-5-yl)alkenoic acid, or a related tetrazole derivative, which antagonises one or more of the actions of thromboxane A₂, together with a compound which inhibits the synthesis of thromboxane A₂. The compositions are useful as medicines in treating a variety of diseases or medical conditions in which thromboxane A₂ and/or other prostanoid contractile substances are involved.

  本发明涉及含有(Z)-(2-烷氧基烷基-或 2-芳氧基烷基-4-苯基-1,3-二氧杂环戊-5-基)烯酸或相关四唑衍生物的新型治疗剂，该治疗剂与抑制血栓素 A₂合成的化合物一起，可拮抗血栓素 A₂的一种或多种作用。 这些组合物可作为药物用于治疗涉及血栓素 A₂和/或其他类固醇收缩物质的多种疾病或病症。